STOCK TITAN

Kintara Therapeutics, Inc. - KTRA STOCK NEWS

Welcome to our dedicated news page for Kintara Therapeutics (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kintara Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kintara Therapeutics 's position in the market.

Rhea-AI Summary
Kintara Therapeutics presents patient case studies at EANO Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
none
-
Rhea-AI Summary
Kintara Therapeutics announces financial results for FY2023, with a net loss of $14.6M compared to $22.7M in FY2022. Cash and cash equivalents as of June 30, 2023, were approximately $1.5M. The company received a $2.0M SBIR grant from NIH for the development of REM-001. Kintara will present data on its lead program, VAL-083, at the EANO Annual Meeting. CEO anticipates announcing top-line data in the international registrational GBM AGILE Study by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.97%
Tags
-
Rhea-AI Summary
Kintara Therapeutics, Inc. will present data from its lead program, VAL-083, for the treatment of recurrent glioblastoma at the 2023 EANO Annual Meeting. The presentation will take place on September 23, 2023, and will include a Phase 2 study of VAL-083 and radiotherapy in newly diagnosed MGMT-unmethylated GBM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences
Rhea-AI Summary
Kintara Therapeutics, Inc. will host a virtual KOL event on VAL-083, a potential first-in-class small molecule chemotherapeutic for glioblastoma, on August 21, 2023. The event will feature experts discussing the current treatment landscape for glioblastoma and Kintara's potential treatment solution. Kintara is advancing VAL-083 in the GBM AGILE Study, with top-line data expected before the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
conferences
-
Rhea-AI Summary
Kintara Therapeutics, Inc. (Nasdaq: KTRA) President and CEO, Robert E. Hoffman, to present at Emerging Growth Conference. The biopharmaceutical company focuses on developing new solid tumor cancer therapies. Investors can register for the conference using the provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences acquisition
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.8%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
Kintara Therapeutics, Inc.

Nasdaq:KTRA

KTRA Rankings

KTRA Stock Data

6.35M
39.03M
0.19%
0.62%
1.69%
Polish and Other Sanitation Good Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO